Legal & General Group
ADVM

Legal & General Group’s Adverum Biotechnologies ADVM Stock Holding History

Legal & General Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,797
Closed -$7.85K – 3420
2025
Q1 		$7.85K Hold
1,797
– – ﹤0.01% 3218
2024
Q4 		$8.39K Hold
1,797
– – ﹤0.01% 3282
2024
Q3 		$12.6K Hold
1,797
– – ﹤0.01% 3220
2024
Q2 		$12.3K Buy
+1,797
New +$16.7K ﹤0.01% 3238
2022
Q2 		– Sell
-678
Closed -$9K – 3516
2022
Q1 		$9K Hold
678
– – ﹤0.01% 3417
2021
Q4 		$12K Sell
678
-1,938
-74% -$38.8K ﹤0.01% 3423
2021
Q3 		$57K Buy
2,616
+1,156
+79% +$29.5K ﹤0.01% 2944
2021
Q2 		$51K Sell
1,460
-366
-20% -$19.7K ﹤0.01% 2938
2021
Q1 		$180K Buy
1,826
+41
+2% +$4.92K ﹤0.01% 2474
2020
Q4 		$194K Sell
1,785
-8
-0.4% -$990 ﹤0.01% 2432
2020
Q3 		$184K Sell
1,793
-156
-8% -$23.4K ﹤0.01% 2370
2020
Q2 		$407K Buy
1,949
+718
+58% +$127K ﹤0.01% 2217
2020
Q1 		$131K Sell
1,231
-78
-6% -$9.09K ﹤0.01% 2344
2019
Q4 		$150K Buy
1,309
+421
+47% +$37.1K ﹤0.01% 2470
2019
Q3 		$48K Hold
888
– – ﹤0.01% 2746
2019
Q2 		$98K Sell
888
-88
-9% -$7.28K ﹤0.01% 2533
2019
Q1 		$51K Buy
976
+165
+20% +$6.67K ﹤0.01% 2702
2018
Q4 		$26K Hold
811
– – ﹤0.01% 2972
2018
Q3 		$49K Hold
811
– – ﹤0.01% 2778
2018
Q2 		$43K Buy
+811
New +$48.8K ﹤0.01% 2811
2017
Q2 		– Sell
-448
Closed -$12K – 3354
2017
Q1 		$12K Buy
448
+149
+50% +$4.24K ﹤0.01% 3166
2016
Q4 		$9K Buy
299
+268
+865% +$8.76K ﹤0.01% 3221
2016
Q3 		$1K Hold
31
– – ﹤0.01% 2868
2016
Q2 		$1K Hold
31
– – ﹤0.01% 2901
2016
Q1 		$2K Hold
31
– – ﹤0.01% 2776
2015
Q4 		$3K Hold
31
– – ﹤0.01% 2793
2015
Q3 		$3K Hold
31
– – ﹤0.01% 2791
2015
Q2 		$5K Hold
31
– – ﹤0.01% 2766
2015
Q1 		$12K Hold
31
– – ﹤0.01% 2759
2014
Q4 		$17K Buy
+31
New +$11.9K ﹤0.01% 2638

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group's ADVM Position: Q2 2025 in Review

Legal & General Group sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 1,797 shares — an estimated $7.85K sold.

Legal & General Group first reported a position in ADVM in Q4 2014 and held it in 30 quarters. The position peaked at $407K in Q2 2020. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.

  • Legal & General Group reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 1,797 Adverum Biotechnologies shares in Q2 2025, an estimated $7.85K.
  • Legal & General Group first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 30 quarters.
  • Legal & General Group's Adverum Biotechnologies position peaked at $407K in Q2 2020.
  • 58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.